Drug Profile


Alternative Names: AP 1007; AP 1431; AP 1450; AP 1451; ISIS 2302

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Atlantic Healthcare
  • Class Anti-inflammatories; Antipsoriatics; Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Pouchitis; Ulcerative colitis

Highest Development Phases

  • Preregistration Pouchitis
  • Phase III Ulcerative colitis
  • Preclinical Crohn's disease
  • Discontinued Asthma; Inflammation; Psoriasis; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 18 Sep 2017 Atlantic Pharmaceuticals initiates enrolment a phase III trial in France, Italy, Ireland, Netherlands, and United Kingdom after December 2015 (NCT02525523)
  • 12 Jun 2017 Alicaforsen tablet is available for licensing in Canada, Japan, World (excluding USA, Europe) as of 12 Jun 2017.
  • 12 Jun 2017 Preclinical trials in Crohn's disease in Japan, USA, Canada, Europe (PO) (Atlantic Healthcare pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top